Welcome to our dedicated page for Spruce Biosciences SEC filings (Ticker: SPRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spruce Biosciences, Inc. (SPRB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, and its filings offer detailed insight into clinical programs, financing arrangements, and corporate governance.
Investors can review current reports on Form 8-K that describe material events such as the company’s loan and security agreement with Avenue Venture Opportunities Fund II, L.P. for up to $50.0 million in term loans tied to regulatory and commercial milestones for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). Other 8-K filings cover a private placement of common stock and pre-funded warrants with institutional investors, conditional Nasdaq approval and resumption of trading on the Nasdaq Capital Market, reverse stock split implementation, quarterly financial results, and changes in the composition of the board of directors.
Spruce’s filings also detail equity and compensation structures, including option repricing actions for certain outstanding stock options and the non-employee director compensation policy under which new directors such as Keli Walbert receive stock option grants and cash retainers. These documents help clarify how the company uses equity incentives and capital structure adjustments to support its development and listing objectives.
Through this page, you can monitor Spruce’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) when filed, which expand on risk factors, financial statements, and management’s discussion of operations. Form 4 and related insider transaction reports, when available, can be used to track trading activity by officers and directors. Stock Titan’s AI tools summarize lengthy filings, highlight key terms in financing agreements, and surface important disclosures related to TA-ERT’s development path, Nasdaq listing status, and the company’s liquidity and capital resources.
Hooks Corwin Dale reported acquisition or exercise transactions in this Form 4 filing.
Spruce Biosciences, Inc. reported that Chief Commercial Officer Corwin Dale Hooks received a grant of 11,000 Restricted Stock Units. Each RSU represents a contingent right to one share of common stock. The units vest in four equal 25% installments each March 15 from 2027 through 2030, conditioned on continued service.
SPRUCE BIOSCIENCES, INC. filed a Form 3 identifying Corwin Dale Hooks, its Chief Commercial Officer, as a reporting person. The filing lists no transactions, indicating that no purchases, sales, acquisitions, or dispositions of SPRB securities are reported in this initial ownership statement.
Spruce Biosciences is offering up to
The prospectus supplement states proceeds may be used to fund clinical programs and for general corporate purposes, including working capital, operating expenses and capital expenditures. The assumed illustrative offering price referenced is
Spruce Biosciences, Inc. entered a new Open Market Sale agreement with Jefferies that allows at‑the‑market issuances of common stock under its existing shelf registration, replacing a 2022 sales agreement. The company also highlighted progress for tralesinidase alfa enzyme replacement therapy (TA‑ERT) for Sanfilippo syndrome type B following positive FDA Type B meetings and is preparing a biologics license application targeted for the fourth quarter of 2026.
For 2025, Spruce reported cash and cash equivalents of $48.9 million as of December 31, 2025, excluding $15.0 million of loan proceeds received in January 2026, and expects this cash to fund operations into early 2027. Research and development expenses fell to $19.5 million from $46.4 million in 2024, while general and administrative expenses rose to $17.0 million from $14.6 million. Total operating expenses declined to $36.5 million from $61.1 million, and net loss narrowed to $39.0 million from $53.0 million.
Spruce secured a growth capital loan facility of up to $50 million from Avenue Capital Group, including an initial fully funded $15 million tranche and three additional tranches subject to conditions. The company appointed Corwin Dale Hooks as Chief Commercial Officer with a $480,000 base salary, target bonus up to 40% of salary, and an inducement restricted stock unit grant for 11,000 shares vesting over four years to support potential commercialization of TA‑ERT.
Spruce Biosciences files its Annual Report outlining a high‑risk but focused rare‑disease strategy and a challenging financial position. The company highlights substantial doubt about its ability to continue as a going concern and says it lacks sufficient working capital for the next twelve months without new funding.
Its lead program, TA‑ERT, targets ultra‑rare MPS IIIB, where no FDA‑approved therapies exist. Long‑term studies showed normalization of key biomarkers and stabilization of cognitive function, and the FDA has agreed that CSF HS‑NRE may support accelerated approval if a confirmatory Phase 3 trial is started during biologics license review. Spruce is preparing a BLA submission, now anticipated in late 2026.
The report also details earlier‑stage assets, including tildacerfont with the Cortibon diagnostic for major depressive disorder, where a Phase 2 trial was discontinued after a serious liver enzyme elevation, and SPR202 for congenital adrenal hyperplasia, licensed from HBM with milestones up to
Spruce Biosciences, Inc. reported a joint Schedule 13G showing that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial interests in roughly 103,000 shares of common stock, representing about 9.6% of the class on the cover pages.
The filing states these holdings are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers, and includes a Joint Filing Agreement dated
Carlyle-affiliated entities and Abingworth funds report beneficial ownership of 50,893 shares of Spruce Biosciences common stock, equal to about 4.7% of the company. This percentage is based on 1,070,370 shares outstanding as of November 7, 2025, and reflects a 1-for-75 reverse stock split completed in August 2025.
The position includes 38,620 shares held by Abingworth Bioventures VII LP, 1,233 shares issuable upon stock options and 11,040 shares issuable upon standard warrants, all exercisable within 60 days. The filing notes that the reporting persons have ceased to be beneficial owners of more than five percent of Spruce’s common stock and that no transactions occurred in the past 60 days. It also records the October 2025 resignation of Bali Muralidhar from Spruce’s board of directors.
Spruce Biosciences Schedule 13G: ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of 58,000 shares of Spruce Biosciences common stock, representing
The percent calculation is based on 1,070,370 shares outstanding reported as of
Alyeska Investment Group and related reporting persons disclosed a 5.79% beneficial ownership stake in Spruce Biosciences, Inc. common stock as of December 31, 2025. They report beneficial ownership of 61,670 shares of common stock, with shared voting and investment power over all of these shares and no sole authority.
An exhibit states this stake includes 21,671 shares of common stock, 30,000 PIPE shares, and warrants to purchase 9,999 additional shares. The reported percentage is based on 1,065,672 Spruce Biosciences common shares outstanding, as set out in a prospectus filed on December 12, 2025. The filers certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Citadel-affiliated funds and Kenneth Griffin report a 6.5% passive stake in Spruce Biosciences. The group may be deemed to beneficially own 70,035 shares of common stock, based on 1,070,370 shares outstanding as of November 7, 2025. Ownership is held through Citadel CEMF Investments Ltd. and Citadel Securities, with all voting and dispositive powers reported as shared, not sole. The filing is on a Schedule 13G/A basis, and the reporting persons certify the shares were not acquired to change or influence control of Spruce Biosciences.